| A randomized trial of bevacizumab for newly diagnosed glioblastoma MR Gilbert, JJ Dignam, TS Armstrong, JS Wefel, DT Blumenthal, ... New England Journal of Medicine 370 (8), 699-708, 2014 | 3095 | 2014 |
| Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial DW Andrews, CB Scott, PW Sperduto, AE Flanders, LE Gaspar, ... The Lancet 363 (9422), 1665-1672, 2004 | 3003 | 2004 |
| Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases PW Sperduto, N Kased, D Roberge, Z Xu, R Shanley, X Luo, PK Sneed, ... Journal of Clinical Oncology 30 (4), 419-425, 2012 | 1543 | 2012 |
| Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402 G Cairncross, M Wang, E Shaw, R Jenkins, D Brachman, J Buckner, ... Journal of clinical oncology 31 (3), 337-343, 2013 | 1295 | 2013 |
| A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database PW Sperduto, B Berkey, LE Gaspar, M Mehta, W Curran International Journal of Radiation Oncology* Biology* Physics 70 (2), 510-514, 2008 | 1184 | 2008 |
| Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II … V Gondi, SL Pugh, WA Tome, C Caine, B Corn, A Kanner, H Rowley, ... Journal of Clinical Oncology 32 (34), 3810-3816, 2014 | 1165 | 2014 |
| Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial MR Gilbert, M Wang, KD Aldape, R Stupp, ME Hegi, KA Jaeckle, ... Journal of clinical oncology 31 (32), 4085-4091, 2013 | 1126 | 2013 |
| Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients PW Sperduto, ST Chao, PK Sneed, X Luo, J Suh, D Roberge, A Bhatt, ... International Journal of Radiation Oncology* Biology* Physics 77 (3), 655-661, 2010 | 1117 | 2010 |
| Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma JC Buckner, EG Shaw, SL Pugh, A Chakravarti, MR Gilbert, GR Barger, ... New England Journal of Medicine 374 (14), 1344-1355, 2016 | 1080 | 2016 |
| Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate … ME Hegi, L Liu, JG Herman, R Stupp, W Wick, M Weller, MP Mehta, ... Journal of clinical oncology 26 (25), 4189-4199, 2008 | 1036 | 2008 |
| Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial PD Brown, S Pugh, NN Laack, JS Wefel, D Khuntia, C Meyers, A Choucair, ... Neuro-oncology 15 (10), 1429-1437, 2013 | 971 | 2013 |
| Response assessment criteria for brain metastases: proposal from the RANO group NU Lin, EQ Lee, H Aoyama, IJ Barani, DP Barboriak, BG Baumert, ... The lancet oncology 16 (6), e270-e278, 2015 | 950 | 2015 |
| Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions PY Wen, M Weller, EQ Lee, BM Alexander, JS Barnholtz-Sloan, ... Neuro-oncology 22 (8), 1073-1113, 2020 | 908 | 2020 |
| Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group … G Cairncross, B Berkey, E Shaw, R Jenkins, B Scheithauer, D Brachman, ... Journal of Clinical Oncology 24 (18), 2707-2714, 2006 | 865 | 2006 |
| Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: phase III trial NRG oncology CC001 PD Brown, V Gondi, S Pugh, WA Tome, JS Wefel, TS Armstrong, JA Bovi, ... Journal of Clinical Oncology 38 (10), 1019-1029, 2020 | 709 | 2020 |
| Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial CA Meyers, JA Smith, A Bezjak, MP Mehta, J Liebmann, T Illidge, ... Journal of clinical oncology 22 (1), 157-165, 2004 | 693 | 2004 |
| A multiinstitutional outcome and prognostic factor analysis of radiosurgery for resectable single brain metastasis RM Auchter, JP Lamond, E Alexander III, JM Buatti, R Chappell, ... International Journal of Radiation Oncology* Biology* Physics 35 (1), 27-35, 1996 | 691 | 1996 |
| Image guidance for precise conformal radiotherapy TR Mackie, J Kapatoes, K Ruchala, W Lu, C Wu, G Olivera, L Forrest, ... International Journal of Radiation Oncology* Biology* Physics 56 (1), 89-105, 2003 | 690 | 2003 |
| Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with … L Souhami, W Seiferheld, D Brachman, EB Podgorsak, M Werner-Wasik, ... International Journal of Radiation Oncology* Biology* Physics 60 (3), 853-860, 2004 | 688 | 2004 |
| Estimating survival in patients with lung cancer and brain metastases: an update of the graded prognostic assessment for lung cancer using molecular markers (Lung-molGPA) PW Sperduto, TJ Yang, K Beal, H Pan, PD Brown, A Bangdiwala, ... JAMA oncology 3 (6), 827-831, 2017 | 666 | 2017 |
Walter CurranChief of Piedmont Oncology InstituteVerified email at piedmont.org
